Cancer Therapy
Phase II results presented on Perifosine for prostate cancer
Published in Cancer Weekly, June 14th, 2005
AEterna Zentaris, Inc., (AEZ; AEZS) announced that its North American partner for perifosine, Keryx Biopharmaceuticals, Inc., (KERX) disclosed that data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, demonstrated the tolerability and potential efficacy of perifosine in the treatment of patients with biochemically recurrent hormone-sensitive prostate cancer (HSPC).
This study was conducted by a consortium of cancer centers under the leadership of the University of California, Davis pursuant to a Collaborative Research and Development Agreement (CRADA) between Keryx and the National Cancer Institute. Perifosine is...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-06-14)
More Articles from Cancer Weekly
- Chemotherapy
Feasibility of individualized chemotherapy treatment for breast cancer analyzed - Head & Neck Cancer
Accuracy of combined PET/CT scans compared to individual PET or CT scans - Healthcare Costs
Costs for cancer treatment at home or in the hospital weighed - Kidney Transplantation
Administration methods of antithymocyte globulins in renal transplant patients - Radioprotectors
Amifostine used as radioprotector of salivary glands in radioiodine therapy - Acute Myeloid Leukemia
New findings in acute myeloid leukemia described - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
